The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin (GemCis) in patients (pts) with advanced biliary tract cancer (BTC): TOPAZ-1.
 
Do-Youn Oh
No Relationships to Disclose
 
Aiwu Ruth He
No Relationships to Disclose
 
Shukui Qin
No Relationships to Disclose
 
Li-Tzong Chen
No Relationships to Disclose
 
Takuji Okusaka
No Relationships to Disclose
 
Arndt Vogel
No Relationships to Disclose
 
Jin Won Kim
No Relationships to Disclose
 
Thatthan Suksombooncharoen
No Relationships to Disclose
 
Myung Ah Lee
No Relationships to Disclose
 
Masayuki Kitano
No Relationships to Disclose
 
Howard A. Burris III
No Relationships to Disclose
 
Mohamed Bouattour
No Relationships to Disclose
 
Suebpong Tanasanvimon
No Relationships to Disclose
 
Renata Zaucha
No Relationships to Disclose
 
Antonio Avallone
No Relationships to Disclose
 
Juan Cundom
No Relationships to Disclose
 
Nana Rokutanda
No Relationships to Disclose
 
Gordon Cohen
No Relationships to Disclose
 
Juan W. Valle
Honoraria - Ipsen
Consulting or Advisory Role - Agios; Aptitude Health; AstraZeneca; Baxter; Cantargia AB; Debiopharm Group; Genoscience Pharma; Hutchison MediPharma; Imaging Equipment Limited; Incyte; Ipsen; Keocyt; Medivir; Merck; Mundipharma; Novartis; Nucana; PCI Biotech; Pfizer; Pieris Pharmaceuticals; QED Therapeutics; SERVIER; Sirtex Medical; Wren Laboratories; Zymeworks
Speakers' Bureau - Imaging Equipment Limited; Incyte; Ipsen; Mylan; Novartis; Nucana; SERVIER
Travel, Accommodations, Expenses - Lilly; Nucana; Roche